$RYES
Rise Gold Corp. Stock $ryes

$ryes Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-K Financial Statement

#000106299324018073 Filed on October 29, 2024

Income Statement

Concept	2024 Q4	2024
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses
YoY Change
Operating Profit
YoY Change
Interest Expense	$96.20K	$306.2K
YoY Change	51.4%	-6.66%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income
YoY Change
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$628.4K	-$3.566M
YoY Change	-54.41%	-2.59%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.01	-$0.08
Diluted Earnings Per Share	-$0.01	-$0.08
COMMON SHARES
Basic Shares Outstanding	55.79M shares	47.00M shares
Diluted Shares Outstanding	55.79M shares	47.00M shares

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$279.7K	$243.7K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses	$152.1K	$117.5K
Receivables
Other Receivables
Total Short-Term Assets	$954.5K	$894.6K
YoY Change	18.11%	-8.79%
LONG-TERM ASSETS
Property, Plant & Equipment		$0.00
YoY Change		-100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$4.240M	$4.261M
YoY Change	-9.26%	-8.91%
TOTAL ASSETS
Total Short-Term Assets	$954.5K	$894.6K
Total Long-Term Assets	$4.240M	$4.261M
Total Assets	$5.194M	$5.155M
YoY Change	-5.22%	-8.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.527M	$2.662M
YoY Change	152.3%	423.35%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.527M	$2.662M
Total Long-Term Liabilities
Total Liabilities	$2.793M	$2.778M
YoY Change	1.38%	33.13%
SHAREHOLDERS EQUITY
Retained Earnings	-$30.86M	-$30.23M
YoY Change	10.04%	13.37%
Common Stock	$55.79K	$55.79K
YoY Change	38.21%	38.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.401M	$2.378M
YoY Change
Total Liabilities & Shareholders Equity	$5.194M	$5.155M
YoY Change	-5.22%	-8.89%

Cashflow Statement

Concept	2024 Q4	2024
OPERATING ACTIVITIES
Net Income	-$628.4K	-$3.566M
YoY Change	-54.41%	-2.59%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$455.0K	-$2.213M
YoY Change	-11.28%	-10.63%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$21.00K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$200.0K
YoY Change		-20.0%
Cash From Financing Activities	$470.0K	$1.699M
YoY Change	6.61%	-38.52%
NET CHANGE
Cash From Operating Activities	-$455.0K	-$2.213M
Cash From Investing Activities	$21.00K
Cash From Financing Activities	$470.0K	$1.699M
Net Change In Cash	$36.02K	-$514.6K
YoY Change	-150.03%	-279.71%
FREE CASH FLOW
Cash From Operating Activities	-$455.0K	-$2.213M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024	dei	Document Transition Report DocumentTransitionReport	false
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55785106	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40362800	shares
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	233895	usd
CY2023Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	15434000	usd
CY2024	dei	Entity Address Address Line1 EntityAddressAddressLine1	650 - 669 Howe Street
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46995567	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36393029	shares
CY2024	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	140015	usd
CY2023	us-gaap	Interest Expense InterestExpense	328097	usd
CY2024	dei	Local Phone Number LocalPhoneNumber	260-4577
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2024Q1	dei	Entity Public Float EntityPublicFloat	6235695	usd
CY2024	dei	Auditor Location AuditorLocation	Vancouver, Canada
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40362800	shares
CY2024Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	18696000	usd
CY2024	us-gaap	Interest Expense InterestExpense	306246	usd
CY2024	ryes	Class Of Warrant Or Right Number Of Warrants Granted During Period ClassOfWarrantOrRightNumberOfWarrantsGrantedDuringPeriod	575000	shares
CY2024	ryes	Class Of Warrant Or Right Granted During Period Exercise Price ClassOfWarrantOrRightGrantedDuringPeriodExercisePrice	0.6
CY2024	ryes	Class Of Warrant Or Right Granted During Period Fair Value Per Warrant ClassOfWarrantOrRightGrantedDuringPeriodFairValuePerWarrant	154218	usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.1
	ryes	Number Of Common Share Purchase Warrants Issued NumberOfCommonSharePurchaseWarrantsIssued	6308310	shares
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--07-31
CY2024	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	30-0692325
CY2024	dei	Auditor Firm AuditorFirmId	731
CY2024	dei	Auditor Name AuditorName	DAVIDSON & COMPANY LLP
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	243669	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	758272	usd
CY2024Q3	us-gaap	Receivables Net Current ReceivablesNetCurrent	21971	usd
CY2023Q3	us-gaap	Receivables Net Current ReceivablesNetCurrent	82529	usd
CY2024Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	117468	usd
CY2023Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	140042	usd
CY2024Q3	ryes	Assets Held For Sale AssetsHeldForSale	511530	usd
CY2023Q3	ryes	Assets Held For Sale AssetsHeldForSale	0	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	894638	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	980843	usd
CY2024Q3	us-gaap	Mineral Properties Net MineralPropertiesNet	4149053	usd
CY2023Q3	us-gaap	Mineral Properties Net MineralPropertiesNet	4149053	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	528465	usd
CY2024Q3	ryes	Deferred Financing Asset DeferredFinancingAsset	111707	usd
CY2023Q3	ryes	Deferred Financing Asset DeferredFinancingAsset	0	usd
CY2024Q3	us-gaap	Assets Assets	5155398	usd
CY2023Q3	us-gaap	Assets Assets	5658361	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	874589	usd
CY2023Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	457412	usd
CY2024Q3	us-gaap	Loans Payable Current LoansPayableCurrent	1658060	usd
CY2023Q3	us-gaap	Loans Payable Current LoansPayableCurrent	0	usd
CY2024Q3	ryes	Payable To Related Parties Current PayableToRelatedPartiesCurrent	128949	usd
CY2023Q3	ryes	Payable To Related Parties Current PayableToRelatedPartiesCurrent	51159	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2661598	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	508571	usd
CY2024Q3	us-gaap	Long Term Loans Payable LongTermLoansPayable	0	usd
CY2023Q3	us-gaap	Long Term Loans Payable LongTermLoansPayable	1437914	usd
CY2024Q3	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	116130	usd
CY2023Q3	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	0	usd
CY2024Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	usd
CY2023Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	140015	usd
CY2024Q3	us-gaap	Liabilities Liabilities	2777728	usd
CY2023Q3	us-gaap	Liabilities Liabilities	2086500	usd
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	55785	usd
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	40363	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	32660586	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	30304568	usd
CY2024Q3	ryes	Cumulative Translation Adjustment CumulativeTranslationAdjustment	104084	usd
CY2023Q3	ryes	Cumulative Translation Adjustment CumulativeTranslationAdjustment	104084	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-30234617	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-26668986	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	2377670	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	3571861	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5155398	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5658361	usd
CY2024	us-gaap	Accretion Expense AccretionExpense	122920	usd
CY2023	us-gaap	Accretion Expense AccretionExpense	149505	usd
CY2024	us-gaap	Legal Fees LegalFees	310718	usd
CY2023	us-gaap	Legal Fees LegalFees	565885	usd
CY2024	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	118022	usd
CY2023	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	81209	usd
CY2024	ryes	Filing And Regulatory Expense FilingAndRegulatoryExpense	38910	usd
CY2023	ryes	Filing And Regulatory Expense FilingAndRegulatoryExpense	57751	usd
CY2024	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-15421	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-45134	usd
CY2024	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	445028	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	363287	usd
CY2024	ryes	Geological Mineral And Prospect Costs GeologicalMineralAndProspectCosts	808832	usd
CY2023	ryes	Geological Mineral And Prospect Costs GeologicalMineralAndProspectCosts	772636	usd
CY2024	us-gaap	Interest Expense Other InterestExpenseOther	306246	usd
CY2023	us-gaap	Interest Expense Other InterestExpenseOther	328097	usd
CY2024	us-gaap	Professional Fees ProfessionalFees	1000394	usd
CY2023	us-gaap	Professional Fees ProfessionalFees	757769	usd
CY2024	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	58361	usd
CY2023	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	183340	usd
CY2024	us-gaap	Salaries And Wages SalariesAndWages	89296	usd
CY2023	us-gaap	Salaries And Wages SalariesAndWages	135000	usd
CY2024	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	345507	usd
CY2023	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	466527	usd
CY2024	us-gaap	Profit Loss ProfitLoss	-3659655	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-3906140	usd
CY2024	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	140015	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	233895	usd
CY2024	ryes	Write Off On Payable WriteOffOnPayable	64356	usd
CY2023	ryes	Write Off On Payable WriteOffOnPayable	0	usd
CY2024	ryes	Other Income Operating OtherIncomeOperating	18365	usd
CY2023	ryes	Other Income Operating OtherIncomeOperating	11863	usd
CY2024	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3565631	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3660382	usd
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.1
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46995567	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36393029	shares
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-3565631	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3660382	usd
CY2024	us-gaap	Interest Expense InterestExpense	306246	usd
CY2023	us-gaap	Interest Expense InterestExpense	328097	usd
CY2024	us-gaap	Depreciation And Amortization DepreciationAndAmortization	16935	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	22971	usd
CY2024	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	345507	usd
CY2023	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	466527	usd
CY2024	us-gaap	Accretion Expense AccretionExpense	122920	usd
CY2023	us-gaap	Accretion Expense AccretionExpense	149505	usd
CY2024	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	140015	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	233895	usd
CY2024	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-60558	usd
CY2023	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-2828	usd
CY2024	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-22574	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-289260	usd
CY2024	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	539917	usd
CY2023	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	135470	usd
CY2024	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	77790	usd
CY2023	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	23141	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2213199	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2476478	usd
CY2024	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	1898596	usd
CY2023	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	2985423	usd
CY2024	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	200000	usd
CY2023	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	250000	usd
CY2024	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	27409	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1698596	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2762832	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-514603	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	286354	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	758272	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	471918	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	243669	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	758272	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3598666	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2985423	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	27409	usd
CY2023	ryes	Warrants Issued For Financing Expense WarrantsIssuedForFinancingExpense	154218	usd
CY2023	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	466527	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3660382	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3571861	usd
CY2024	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1898596	usd
CY2024	ryes	Warrants Issued For Credit Facility WarrantsIssuedForCreditFacility	127337	usd
CY2024	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	345507	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-3565631	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2377670	usd
CY2024	us-gaap	Nature Of Operations NatureOfOperations	<div> <div> <div> <div> <div> <div> <div> <div> <div> <p style="margin-left:36pt;text-indent:-36pt;text-align:justify;margin-top:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>1.<span style="display:inline-block;width:28.5pt"> </span></strong><strong>NATURE AND CONTINUANCE OF OPERATIONS</strong></span></span></p> <p style="margin-left:36pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Rise Gold Corp. (the "Company") was originally incorporated as Atlantic Resources Inc. in the State of Nevada on February 9, 2007 and is in the exploration stage. On April 11, 2012, the Company merged its wholly-owned subsidiary, Patriot Minefinders Inc., a Nevada corporation, in and to the Company to effect a name change to Patriot Minefinders Inc. On January 14, 2015, the Company completed a name change to Rise Resources Inc. in the same manner. On March 29, 2017, the Company changed its name to Rise Gold Corp. These mergers were carried out solely for the purpose of effecting these changes of names.</span></span></p> <p style="margin-left:36pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On September 18, 2020, the Company increased its authorized capital from 40,000,000 shares to 400,000,000 shares. </span></span></p> <p style="margin-left:36pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On January 29, 2016, the Company completed an initial public offering in Canada and began trading on the Canadian Securities Exchange ("CSE") on February 1, 2016.</span></span></p> <p style="margin-left:36pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company is in the early stages of exploration and as is common with any exploration company, it raises financing for its acquisition activities. The accompanying consolidated financial statements have been prepared on the going concern basis, which presumes that the Company will continue operations for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business. The Company has incurred a loss of $3,565,631 for the year ended July 31, 2024 and has accumulated a deficit of $30,234,617. The ability of the Company to continue as a going concern is dependent on the Company's ability to maintain continued support from its shareholders and creditors and to raise additional capital and implement its business plan. There is no assurance that the Company will be able to obtain adequate financing in the future or that such financing will be on terms advantageous to the Company. These events and conditions cast substantial doubt about the Company's ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.</span></span></p> <p style="margin-left:36pt;text-align:justify;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">At July 31, 2024, the Company had working capital deficit of $1,766,960 (2023 - working capital of $472,272).</span></span></p> </div> </div> </div> </div> </div> </div> </div> </div> </div>
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="margin-left:36pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Use of Estimates</strong></span></span></p> <p style="margin-left:35.45pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The preparation of these financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant areas requiring the use of estimates include the carrying value and recoverability of mineral properties and the recognition of deferred tax assets based on the change in unrecognized deductible temporary tax differences. Actual results could differ from those estimates and would impact future results of operations and cash flows.</span></span></p> </div>
CY2024	ryes	Property Plant And Equipment Depreciation Method PropertyPlantAndEquipmentDepreciationMethod	straight-line basis
CY2024Q3	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P15Y
CY2024	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <p style="margin-left:36pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Concentration of credit risk</strong></span></span></p> <p style="margin-left:36pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The financial instrument which potentially subjects the Company to concentration of credit risk is cash. The Company maintains cash in bank accounts that, at times, may exceed federally insured limits However, the Company has not experienced any losses in such accounts and believes it is not exposed to any significant risks on its cash in bank accounts.</span></span></p> </div>
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	243669	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	758272	usd
CY2024Q3	us-gaap	Prepaid Insurance PrepaidInsurance	56922	usd
CY2023Q3	us-gaap	Prepaid Insurance PrepaidInsurance	79758	usd
CY2024Q3	ryes	Prepaid Deposits PrepaidDeposits	48226	usd
CY2023Q3	ryes	Prepaid Deposits PrepaidDeposits	50539	usd
CY2024Q3	ryes	Investor Relations InvestorRelations	12320	usd
CY2023Q3	ryes	Investor Relations InvestorRelations	9745	usd
CY2024Q1	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	1000000	usd
CY2024Q1	us-gaap	Line Of Credit Facility Interest Rate During Period LineOfCreditFacilityInterestRateDuringPeriod	0.12	pure
CY2024Q1	ryes	Class Of Warrant Or Right Number Of Warrants Granted During Period ClassOfWarrantOrRightNumberOfWarrantsGrantedDuringPeriod	1000000	shares
CY2024Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.16
CY2024Q1	ryes	Fair Value Of Warrants Received As Additional Consideration For Loan FairValueOfWarrantsReceivedAsAdditionalConsiderationForLoan	127336	usd
CY2024	ryes	Description Of Additional Warrants DescriptionOfAdditionalWarrants	In addition, for each $100,000 loaned under the arrangement, the Company has agreed to issue to the lender 200,000 additional non-transferable warrants ("Additional Warrants").
CY2024Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.158
CY2023Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.26
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5578511	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.69
	ryes	Number Of Common Share Purchase Warrants Issued NumberOfCommonSharePurchaseWarrantsIssued	6308310	shares
CY2024Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	16711575	shares
CY2024Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.56
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-3565631	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3660382	usd
CY2024	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-998000	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-978000	usd
CY2024	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	27000	usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	703000	usd
CY2024	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	76000	usd
CY2023	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	125000	usd
CY2024	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-350000	usd
CY2023	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-1391000	usd
CY2024	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	-1245000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	-1541000	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q3	ryes	Deferred Tax Assets Mineral Property Interest DeferredTaxAssetsMineralPropertyInterest	477000	usd
CY2023Q3	ryes	Deferred Tax Assets Mineral Property Interest DeferredTaxAssetsMineralPropertyInterest	310000	usd
CY2024Q3	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	116000	usd
CY2023Q3	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	87000	usd
CY2024Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	5232000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	4125000	usd
CY2024Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	5593000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	4348000	usd
CY2024Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5593000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4348000	usd
CY2024Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2024	ryes	Accrued Of Financing Expense On Warrants Issued For Deferred Financing Asset AccruedOfFinancingExpenseOnWarrantsIssuedForDeferredFinancingAsset	127336	usd
CY2024	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment

Files In Submission

Name	View Source	Status
0001062993-24-018073-index-headers.html	Edgar Link	pending
0001062993-24-018073-index.html	Edgar Link	pending
0001062993-24-018073.txt	Edgar Link	pending
0001062993-24-018073-xbrl.zip	Edgar Link	pending
exhibit23-1.htm	Edgar Link	pending
exhibit31-1.htm	Edgar Link	pending
exhibit31-2.htm	Edgar Link	pending
exhibit32-1.htm	Edgar Link	pending
exhibit32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10k.htm	Edgar Link	pending
form10kxz001.jpg	Edgar Link	pending
form10kxz002.jpg	Edgar Link	pending
form10kxz003.jpg	Edgar Link	pending
form10kxz004.jpg	Edgar Link	pending
form10kxz005.jpg	Edgar Link	pending
form10kxz006.jpg	Edgar Link	pending
form10kxz007.jpg	Edgar Link	pending
form10kxz008.jpg	Edgar Link	pending
form10kxz009.jpg	Edgar Link	pending
form10kxz010.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
form10k_htm.xml	Edgar Link	completed
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
ryes-20240731.xsd	Edgar Link	pending
Show.js	Edgar Link	pending
ryes-20240731_cal.xml	Edgar Link	unprocessable
ryes-20240731_def.xml	Edgar Link	unprocessable
ryes-20240731_lab.xml	Edgar Link	unprocessable
ryes-20240731_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RYES
Rise Gold Corp. Stock $ryes

2024 Q4 Form 10-K Financial Statement

#000106299324018073 Filed on October 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RYES Rise Gold Corp. Stock $ryes

2024 Q4 Form 10-K Financial Statement

#000106299324018073 Filed on October 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RYES
Rise Gold Corp. Stock $ryes